70 citations
,
September 2017 in “Expert opinion on therapeutic patents” The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.
13 citations
,
September 2018 in “Journal of the American Academy of Dermatology” The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
July 2025 in “Jurnal Farmasi Sains dan Praktis” Most adverse reactions to the treatment were mild, with nausea being the most common.
March 2026 in “Mendeley Data” rwSALT accurately measures hair regrowth in alopecia areata using scalp photos.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
January 2026 in “Annals of Dermatology” Alitretinoin may help treat mild to moderate alopecia areata.
4 citations
,
January 1996 in “PubMed” October 2025 in “Journal of Clinical Medicine” Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
August 2022 in “Dermatologic Therapy”
Current treatments for alopecia areata often fail to achieve and maintain significant hair regrowth.
November 2022 in “Skin appendage disorders” The Spanish version of the WAA-QoL questionnaire is reliable and valid for assessing quality of life in women with hair loss.
December 2024 in “Kırıkkale Üniversitesi Tıp Fakültesi Dergisi” Chromosomal microarray analysis is important for diagnosing rare genetic variations and guiding treatment.
22 citations
,
April 2024 in “Indian Journal of Microbiology” November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
14 citations
,
January 2017 in “Pharmacological Reports” TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
September 2023 in “Journal of The American Academy of Dermatology” The document's conclusion cannot be provided because the content is not available.
January 2022 in “Al-Azhar Medical Journal” Higher antigliadin antibody levels are linked to alopecia areata severity.
5 citations
,
October 2015 in “The Egyptian Journal of Otolaryngology” Alopecia areata patients may have hearing loss linked to the condition's severity and duration.
6 citations
,
August 2004 in “Journal of Chemical Information and Computer Sciences” The research found a link between certain molecular features and the biological activity of BC3, which can help identify or create new active compounds.
January 2023 in “Springer eBooks”
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
2 citations
,
September 2015 in “Dicle Medical Journal” The document's conclusion cannot be provided as the content is not in a language that I can process. Please provide content in English for a summary.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
6 citations
,
July 2022 in “Journal of health economics and outcomes research” Adolescents with severe alopecia incur significantly higher healthcare costs.
4 citations
,
June 2016 in “Rossiiskii Zhurnal Kozhnykh i Venericheskikh Boleznei” Combining iron supplements with Qilib lotion is more effective for treating hair loss from iron deficiency.
December 2023 in “JEADV Clinical Practice” A woman's hair grew back with baricitinib treatment, but she developed a temporary hairy tongue that was treated with regular tongue brushing.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
42 citations
,
July 2013 in “Gene” IL-4 gene variation may increase the risk of alopecia areata in Turkish people.